Stay updated with breaking news from Factor Viii. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers have developed an algorithm to help clinicians determine whether patients have acquired hemophilia A (AHA), a rare bleeding disorder that mainly affects elderly men with medical problems.
Also in TTHealthWatch: gene therapy for hemophilia A
One year after infusion of a gene-transfer product, patients with the bleeding disorder had significant improvements in clotting factor production and dramatic reductions in factor concentrate use.
Genetic solutions to hemophilia are promising, but application to pediatrics could take years
New approaches to treating hemophilia may soon replace the decades-old approach of using factor concentrates to control bleeding in patients with hemophilia A and hemophilia B.